Opinion
Video
Author(s):
The expert panel recaps and synthesizes key points and conclusions from each presentation and discussion over the course of the program.
Blinatumomab Plus Consolidation Chemotherapy Extends OS in MRD– B-Cell Precursor ALL
Bui and Kelly Discuss the Utility of Nab-Sirolimus in Advanced Malignant PEComa
FDA Accepts Resubmission of BLA for Remestemcel-L in Pediatric Steroid-Refractory aGVHD
Paik Provides Insights Into Tepotinib Treatment in NSCLC Harboring MET Exon 14 Skipping Alterations
Exploring Unmet Needs to Optimize Neoadjuvant Therapy in Resectable CRC
Autologous TIL Therapy Plus Pembrolizumab Under Exploration in PD-L1–Resistant Advanced HNSCC
MRD Testing Requires Prospective Data to Assess Clinical Utility in Breast Cancer
Dr Rotow on the Impact of Biomarker Testing on NSCLC Treatment Outcomes
Dr Sabari on Barriers to Biomarker Testing in NSCLC
Dr Backhus on Surgical Eligibility in Borderline Resectable NSCLC